Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

The United Laboratories International Holdings Limited and Novo Nordisk (NVO) announced earlier that Novo Nordisk and TUL’s wholly-owned ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

The United Laboratories, Novo Nordisk ink exclusive global license agreement for UBT251: Guangdong, China Wednesday, March 26, 2025, 10:00 Hrs [IST] The United Laboratories Intern ...